Who We Are

We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases.

Our Pipeline

Our lead product, OC-01, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. OC-01’s novel mechanism of action is designed to reestablish tear film homeostasis by activating natural tear film production.

Latest News


Oyster Point Pharma to Attend the Piper Sandler 32nd Annual Virtual Healthcare Conference


Oyster Point Pharma Announces Clinical Data Presentations on OC-01 Nasal Spray for Dry Eye Disease at the American Academy of Ophthalmology 2020 Virtual Annual Meeting